The CGTLive™ Hematology specialty topic page houses the most up-to-date clinical news coverage in the field of hematology gene and cell therapy. It also includes video interviews with key opinion leaders in the field of hematology/oncology about the latest relevant FDA actions, clinical guideline updates, and clinical trial findings related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for various blood disorders.
April 14th 2025
Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications.
Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 66th ASH Annual Meeting
April 26-27, 2025
Register Now!
29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
28th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
View More
New Combination-Based Approaches to Newly Diagnosed MM: What Do the Data, the Experts, and Patients Say?
View More
Medical Crossfire®: Onco-Nurses Exchange Best Practices on PNH Treatment and Symptom Management Along the Patient Care Journey
View More
Show Me Your Care Plan™: How Can Onco-Nurses Improve Patient Care in CML Across the Treatment Continuum?
View More
Show Me Your Care Plan! Managing Breast Cancer Patients Under Current Data for Immuno- and Targeted Therapies, CDK4/6i, ADCs and Beyond
View More
New Combination-Based Approaches to NDMM: What Do the Data, the Experts, and Patients Say?
View More
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Medical Crossfire™: Integrating Recent Evidence into the Treatment of Newly Diagnosed Multiple Myeloma
June 12, 2025
Register Now!
Broadening Horizons in Newly Diagnosed Multiple Myeloma—Exploring New Combination Approaches and Their Impact
View More
Medical Crossfire®: Risk-Adapted Management of Multiple Myeloma—How Do the Experts Do It?
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
9th Annual Live Medical Crossfire®: Hematologic Malignancies
July 26, 2025
Register Now!
Exploring the Dynamic Shifts in the MDS Treatment Paradigm: Unveiling Advances in Disease Modifying Therapies, Spotlight on Cutting-Edge Clinical Trials, and the Latest Approvals
View More
Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options
View More
New Horizons in Multiple Myeloma Treatment – Selection and Sequencing From Newly Diagnosed to Relapsed/Refractory Disease
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
Medical Crossfire®: Uncovering The Clinical Utility of Combination Therapies and MRD Assessment in Newly Diagnosed Multiple Myeloma
View More
Community Practice Connections™: 8th Annual School of Nursing Oncology™
View More
SimulatEd™: Patient-Centered Care to Improve Outcomes in Chronic Lymphocytic Leukemia
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations
View More
Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment
View More
How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma
View More
Dr Neil Minkoff on Hopes, Payer Reactions If a Gene Therapy Is Approved for Sickle Cell Disease
September 6th 2019Neil Minkoff, MD, chief medical officer and vice president, EmpiraMed, discusses his hopes if the first gene therapy for sickle cell disease is approved and if he has any concerns with payer reactions.
Ascending Dose Study Demonstrates Safety, Efficacy of Voxelotor in Sickle Cell Disease
May 15th 2019Voxelotor, a first-in-class oral therapy, is both safe and effective in sickle cell disease, according to a phase 1/2 randomized study assessing the drug. These findings were consistent across all doses, ranging from 500 to 1000 mg.
Sophie Schmitz on the Importance of Considering Value of Gene Therapies, Not Just Cost
March 28th 2019Gene therapy provides an opportunity for every patient to become not a patient, to become an individual, and you can’t put a cost on that, explained Sophie Schmitz, BA, MA, managing partner, Partners4Access.
Dose-Confirmation Study for Hemophilia B Gene Therapy Underway
August 24th 2018The first patient has been treated in a phase 2b dose-confirmation study of AMT-061, an investigational gene therapy for the treatment of patients with severe and moderately severe hemophilia B. Once the dosing of AMT-061 is confirmed, the safety and efficacy of the therapy will be evaluated in the global phase 3 HOPE-B clinical trial.
FDA Accepts IND Application for BIVV003, a Gene Therapy for Sickle Cell Disease
May 16th 2018The US Food and Drug Administration (FDA) has accepted the Bioverativ's Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell disease.
Two Grants Awarded to Medical College of Wisconsin Researcher
July 11th 2016Researchers discovered a clinically translatable gene therapy protocol, which is a gene delivery system that introduced the production of therapeutic clotting proteins in platelets, so that the inhibition of inactivating antibodies is avoided.